Rituximab en el tratamiento de citopenias autoinmunitarias refractarias a tratamientos convencionales / Role of rituximab in the management of refractory autoimmune cytopenia
An. pediatr. (2003, Ed. impr.)
; 78(6): 389-404, jun. 2013. tab
Article
in Spanish
| IBECS
| ID: ibc-112822
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
Objetivo:
Evaluar el papel del rituximab en el tratamiento de citopenias autoinmunitarias refractarias a tratamientos convencionales. Material ymétodos:
Estudio descriptivo longitudinal constituido por una serie de casos clínicos (n = 7) durante el período comprendido entre 2003 y 2010.Resultados:
Se recogen 7 pacientes 4, trombocitopenia inmune primaria; 2, anemia hemolítica autoinmunitaria, y 1, neutropenia autoinmunitaria. Un paciente había recibido trasplante de progenitores hematopoyéticos. La dosis fue de 375mg/m2/semana. Cuatro pacientes recibieron 4 dosis y 3 pacientes recibieron 2, 6 y 8 dosis cada uno. Cinco de los pacientes (71%) cumplieron criterios de respuesta global (completa en 4 pacientes y parcial en 1). A las 8,5 semanas, respondieron la mitad de los pacientes (rango 3,5-19,5). La mediana de la duración de la respuesta fue de 35,5 semanas (rango 12,5-53,5). El 100% de los respondedores pudo disminuir su tratamiento previo. Se registraron 2 recaídas. No se registran efectos adversos graves.Conclusiones:
El 71% de los pacientes de esta serie responden al tratamiento, disminuyendo el 100% de los respondedores su tratamiento previo. Rituximab es un tratamiento bien tolerado, sin efectos secundarios graves en el período de seguimiento estudiado (AU)ABSTRACT
Objectives:
This study examined the efficacy of rituximab in children with refractory autoimmune cytopenia. Material andmethods:
Longitudinal descriptive study comprising a series of clinical cases (n=7) during the period 2003 to 2010.Results:
A series 7 patients were included (4 had primary immune thrombocytopenia, 2 autoimmune hemolytic anemia, and 1 autoimmune neutropenia). One patient had received stem cell transplantation. Rituximab was administered intravenously to all patients at a dose of 375mg/mg2 weekly. Four patients received 4 doses. Three patients received 2, 6, and 8 doses, respectively. Overall, 5 patients responded (4 complete responses plus 1 partial response). The median time to achieve complete response was 8.5 weeks (range 3.5-19.5 weeks). Two patients achieved complete response in the first 3.5 weeks, and the remaining 3 patients between 8.5 and 19.5 weeks. The median time of response was 35.5 weeks (range 12.5-53.5 weeks). Two patients relapsed. No serious adverse events were recorded.Conclusions:
Overall, seventy one percent of patients in this study respond to treatment, 100% of responders decrease their previous treatment. Rituximab was a well tolerated and no related serious side effects were recorded during the study period (AU)
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Anemia, Refractory
/
Anemia, Hemolytic, Autoimmune
/
Antibodies, Monoclonal
Type of study:
Etiology study
/
Risk factors
Limits:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
Spanish
Journal:
An. pediatr. (2003, Ed. impr.)
Year:
2013
Document type:
Article
Institution/Affiliation country:
Hospital Universitario Niño Jesús/España
/
Hospital Virgen de la Salud/España